{"id":4356,"date":"2024-09-05T10:01:36","date_gmt":"2024-09-05T03:01:36","guid":{"rendered":"https:\/\/www.hivnat.org\/en\/?p=4356"},"modified":"2024-09-05T10:01:38","modified_gmt":"2024-09-05T03:01:38","slug":"a-phase-2a-2b-randomized-placebo-controlled-study-evaluating-safety-immunogenicity-and-therapeutic-efficacy-of-id93-gla-se-vaccination-in-participants-with-rifampicin-susceptible-pulmonary-tb-a","status":"publish","type":"post","link":"https:\/\/www.hivnat.org\/en\/studies\/4356\/","title":{"rendered":"A Phase 2a\/2b Randomized, Placebo-Controlled Study Evaluating Safety, Immunogenicity, and Therapeutic Efficacy of ID93 + GLA-SE Vaccination in Participants with Rifampicin-Susceptible Pulmonary TB ( A5397\/HVTN 603)"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\">The study is a double-blinded, placebo-controlled study with a Phase 2a\u00a0 and a Phase 2b component evaluating safety and immunogenicity of ID93 + GLA-SE, as well as tuberculosis (TB) outcomes. Participants with TB who are receiving locally provided standard of care (SOC) TB treatment will be randomized to receive ID93 + GLA-SE or placebo.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>The study is a double-blinded, placebo-controlled study with a Phase 2a\u00a0 and a Phase 2b component evaluating safety and immunogenicity of ID93 + GLA-SE, as well as tuberculosis (TB) outcomes.&hellip; <\/p>\n","protected":false},"author":3,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[24],"tags":[],"class_list":["post-4356","post","type-post","status-publish","format-standard","hentry","category-studies"],"_links":{"self":[{"href":"https:\/\/www.hivnat.org\/en\/wp-json\/wp\/v2\/posts\/4356","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.hivnat.org\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.hivnat.org\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.hivnat.org\/en\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/www.hivnat.org\/en\/wp-json\/wp\/v2\/comments?post=4356"}],"version-history":[{"count":1,"href":"https:\/\/www.hivnat.org\/en\/wp-json\/wp\/v2\/posts\/4356\/revisions"}],"predecessor-version":[{"id":4357,"href":"https:\/\/www.hivnat.org\/en\/wp-json\/wp\/v2\/posts\/4356\/revisions\/4357"}],"wp:attachment":[{"href":"https:\/\/www.hivnat.org\/en\/wp-json\/wp\/v2\/media?parent=4356"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.hivnat.org\/en\/wp-json\/wp\/v2\/categories?post=4356"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.hivnat.org\/en\/wp-json\/wp\/v2\/tags?post=4356"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}